Radiation synovectomy using 165Dy ferric-hydroxide and oxidative DNA damage in patients with different types of arthritis

Journal of Nuclear Medicine

Volumn 41, Issue 2, 2000, Pages 250-256

  Pirich, Christian ^a   Pilger, Alexander ^b   Schwameis, Eva ^b   Germadnik, Dietmar ^b   Prüfert, Ulrike ^b   Havlik, Ernst ^b   Lang, Susanna ^b   Kvaternik, Herbert ^b   Flores, Juan A ^b   Angelberger, Peter ^b   Wanivenhaus, Axel ^b   Rüdiger, Hugo W ^b   Sinzinger, Helmut ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

Biomarker; Cancer; Cytogenetic damage; Radiation synovectomy

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; BIOLOGICAL MARKER; DNA; DYSPROSIUM IRON HYDROXIDE DY 165; HUMAN IMMUNOGLOBULIN; PERTECHNETIC ACID TC 99M; 8-HYDROXY-2'-DEOXYGUANOSINE; DEOXYGUANOSINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; DYSPROSIUM; FERRIC HYDROXIDE; FERRIC ION; IMMUNOGLOBULIN; RADIOISOTOPE; TECHNETIUM; TECHNETIUM TC 99M IMMUNOGLOBULIN; TUMOR MARKER;

ADULT; AGED; ARTHRITIS; ARTICLE; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DNA DAMAGE; FEMALE; GENOTOXICITY; HUMAN; HUMAN CELL; LYMPH NODE; MALE; MICRONUCLEUS; OXIDATIVE STRESS; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; RADIATION INJURY; SYNOVECTOMY; SYNOVITIS; URINARY EXCRETION; KNEE; RADIATION EXPOSURE; SCINTISCANNING; URINE;

ADULT; ARTHRITIS; DEOXYGUANOSINE; DNA DAMAGE; DYSPROSIUM; FEMALE; FERRIC COMPOUNDS; HUMANS; IMMUNOGLOBULINS; KNEE JOINT; MALE; RADIOISOTOPES; SYNOVITIS; TECHNETIUM; TUMOR MARKERS, BIOLOGICAL;

EID: 0033621981     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. 198Au synoviorthesis. J Rheumatol. 1991;18:734-735.
2. Siegel ME, Siegel HJ, Luck JV. Radiosynovectomy's clinical applications and cost effectiveness: a review. Semin Nucl Med. 1997;27:364-371.
3. De La Chapelle A, Oka M, Rekonen A, Ruotsi A. Chromosome damage after intra-articular injections of radioactive yttrium. Ann Rheum Dis. 1972;31:568-572.
4. Stevenson AC, Bedford J, Dolphin GW, et al. Cytogenetic and scanning study of patients receiving intra-articular injections of gold-198 and yttrium-90. Ann Rheum Dis. 1973;32:112-123.
5. Jalava S. Irradiation synovectomy in experimental arthritis and in human rheumatoid arthritis. Scand J Rheumatol. 1974;2(suppl):1-32.
6. Gumpel JM, Beer TC, Crawley JCW, Farran HEA. Yttrium-90 in persistent synovitis of the knee - a single centre comparison: the retention and extra-articular spread of four Y-90 radiocolloids. Br J Radiol. 1975;48:377-381.
7. Doyle DV, Glass JS, Gow PJ, Daker M, Grahame R. A clinical and prospective chromosomal study of yttrium-90 synovectomy. Rheumatol Rehab. 1977;16:217-222.
8. Lloyd DC, Reeder EJ. Chromosome aberrations and intra-articular yttrium-90. Lancet. 1978;1:617.
9. 90Y synovectomy. Therapiewoche. 1979;29:492-496.
10. Williams PL, Crawley JCL, Freeman AM, Lloyd DC, Gumpel JM. Feasibility of outpatient management after intra-articular yttrium-90: comparisons of two regimens. Br Med J. 1981;282:13-14.
11. Hnatowich DJ, Kramer RI, Sledge CB, Noble J, Shortkoff S. Dysprosium-165 ferric hydroxide macroaggregates for radiation synovectomy. J Nucl Med. 1977;19:303-308.
12. Sledge CB, Zuckerman JD, Zalutsky MR, et al. Treatment of rheumatoid synovitis of the knee with intra-articular injection of dysprosium 165-ferric hydroxide macroaggregates. Arthritis Rheum. 1986;29:153-159.
13. Pirich C, Prüfert U, Havlik E, et al. Monitoring of biodistribution and biokinetics of dysprosium-165 ferric-hydroxide with a shadow-shield whole-body counter. Eur J Nucl Med. 1997;24:398-402.
14. Carrano A, Heddle JA. The fate of chromosome aberrations. J Theor Biol. 1973;38:289-304.
15. Noble J, Jones AG, Davies MA, Sledge CB, Kramer RI, Livni E. Leakage of radioactive particle systems from synovial joint fluid studied with a gamma camera. J Bone Joint Surg. 1983;65A:381-389.
16. Prosser JS, Izard BE, Brown JK, et al. Induction of micronuclei in peripheral blood lymphocytes of patients treated for rheumatoid or osteoarthritis of the knee with dysprosium-165 hydroxide macroaggregates or yttrium-90 silicate. Cytobiosis. 1993;73:7-15.
17. Edmonds J, Smart R, Laurent R, et al. A comparative study of the safety and efficacy of dysprosium-165 hydroxide macro-aggregate and yttrium-90 silicate colloid in radiation synovectomy: a multicenter double-blind trial. Br J Rheumatol. 1994;333:947-953.
18. Erhola M, Toyokuni S, Okada K, et al. Biomarker evidence of DNA oxidation in lung cancer patients: association of urinary 8-hydroxy-2′-desoxyguanosine excretion with radiotherapy, chemotherapy, and response to treatment. FEBS Lett. 1997;409:287-291.
19. Floyd RA, Watson JJ, Wong PK, Altmiller DH, Rickard RC. Hydroxyl free radical adduct of deoxyguanosine: sensitive detection and mechanisms of formation. Free Radical Res. 1986;1:163-172.
20. 99mTc-polyclonal human immunoglobulin. Nucl Med Commun. 1993;14:225-231.
21. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn. 1977;18:481-491.
22. Fenech M. The cytokinesis-block micronucleus assay in nucleated cells. Prog Clin Biol Res. 1990;340B:195-206.
23. Germadnik D, Rüdiger HW. Assay for the determination of urinary 8-hydroxy-2′-deoxyguanosine by high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Sci App. 1997;689:399-403.
24. Clunie G, Lui D, Cullum I, Ell PJ, Edwards JCW. Clinical outcome after one year following samarium-153 particulate hydroxyapatite radiation synovectomy. Scand J Rheumatol. 1996;25:360-366.
25. Gantenberg HW, Wuttke K, Streffer C, Müller WU. Micronuclei in human lymphocytes irradiated in vitro or in vivo. Radiat Res. 1991;128:276-281.
26. Loft S, Vistisen K, Ewertz M, Tjonneland A, Overvad K, Poulsen HE. Oxidative DNA damage estimated by 8-hydroxydeoxyguanosine excretion in humans: influence of smoking, gender, and body mass-index. Carcinogenesis. 1992;13: 2241-2247.
27. Lunec J, Herbert K, Blount S, Griffiths HR, Emery P. 8-hydroxydeoxyguanosine: a marker of oxidative DNA damage in systemic lupus erythematosus. FEBS Lett. 1994;348:131-138.
28. Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J. 1995;313:17-29.
29. Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;37:481-494.
30. Myllykangas-Luosujarvi R, Aho K, Isomaki H. Mortality from cancer in patients with rheumatoid arthritis. Scand J Rheumatol. 1995;24:76-78.
31. Tugwell P, Pincus T, Yogum D, et al. Methotrexate-Cyclosporine Combination Study Group: combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med. 1995;333:137-141.
32. Lih-Brody L, Powell SR, Collier KP, et al. Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. Dig Dis Sci. 1996;41:2078-2086.